The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

Research Article
Free Access

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

Mark C. Genovese

Corresponding Author

E-mail address: [email protected]

Stanford University, Palo Alto, California

Drs. Genovese, Cohen, and Moreland have served as consultants for Amgen, Inc.

Mark C. Genovese, Stanford University, 1000 Welch Road, Suite 203, Palo Alto, CA 94304. Address reprint requests to Pirow Bekker, MD, PhD, Amgen, One Amgen Center Drive, 38‐2‐B, Thousand Oaks, CA, 91320

Pirow Bekker, Amgen, One Amgen Center Drive, 38‐2‐B, Thousand Oaks, CA, 91320

Search for more papers by this author
Stanley Cohen

St. Paul Medical Center, Dallas, Texas

Drs. Genovese, Cohen, and Moreland have served as consultants for Amgen, Inc.Search for more papers by this author
Larry Moreland

University of Alabama at Birmingham

Drs. Genovese, Cohen, and Moreland have served as consultants for Amgen, Inc.Search for more papers by this author
Deborah Lium

Amgen, Thousand Oaks, California

Search for more papers by this author
Sean Robbins

Amgen, Thousand Oaks, California

Search for more papers by this author
Pirow Bekker

Corresponding Author

Amgen, Thousand Oaks, California

Mark C. Genovese, Stanford University, 1000 Welch Road, Suite 203, Palo Alto, CA 94304. Address reprint requests to Pirow Bekker, MD, PhD, Amgen, One Amgen Center Drive, 38‐2‐B, Thousand Oaks, CA, 91320

Pirow Bekker, Amgen, One Amgen Center Drive, 38‐2‐B, Thousand Oaks, CA, 91320

Search for more papers by this author
for the 20000223 Study Group
Members of the 20000223 Study Group are shown in Appendix ASearch for more papers by this author
First published: 06 May 2004
Cited by: 283

Abstract

Objective

To determine the potential for additive or synergistic effects of combination therapy with the selective anti–tumor necrosis factor α agent etanercept and the anti–interleukin‐1 agent anakinra.

Methods

Two hundred forty‐four patients in whom rheumatoid arthritis (RA) was active despite methotrexate therapy were treated with subcutaneous etanercept only (25 mg twice weekly), full‐dosage etanercept (25 mg twice weekly) anakinra (100 mg/day), or half‐dosage etanercept (25 mg once weekly) anakinra (100 mg/day) for 6 months in a double‐blind study at 41 centers in the US. Patients had never previously received anticytokine therapy. Patient response was measured with the American College of Rheumatology (ACR) core set criteria, a health‐related quality‐of‐life questionnaire, and the Disease Activity Score. Safety was assessed by the number of adverse events and clinical laboratory values. Plasma concentrations of both agents and antibody formation against both agents were also assessed.

Results

Combination therapy with etanercept anakinra provided no treatment benefit over etanercept alone, regardless of the regimen, but was associated with an increased safety risk. Thirty‐one percent of the patients treated with full‐dosage etanercept anakinra achieved an ACR 50% response, compared with 41% of the patients treated with etanercept only. This result was not statistically significant (P = 0.914). The incidence of serious infections (0% for etanercept alone, 3.7–7.4% for combination therapy), injection‐site reactions, and neutropenia was increased with combination therapy. Combination therapy had no effect on the pharmacokinetics or immunogenicity of either agent.

Conclusion

Combination therapy with etanercept and anakinra provides no added benefit and an increased risk compared with etanercept alone and is not recommended for the treatment of patients with RA.

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by inflammation that often leads to the progressive destruction of articular structures and significant disability. The etiology of RA remains unclear, but it is thought to be mediated in part by antigen‐driven T cells and macrophages that produce interleukin‐1 (IL‐1) and tumor necrosis factor α (TNFα), 2 cytokines involved in the inflammatory cascade (1-3). Specific blockade of these individual cytokines has recently been shown in large, place‐controlled trials to be safe and effective in the treatment of RA (4-9).

Although selective anticytokine therapy has improved patient outcomes, it does not necessarily produce disease remission. Thus, the more aggressive treatment option of combining anticytokine agents has been explored in animal studies. Combination treatment with anakinra, a recombinant IL‐1 receptor antagonist (IL‐1Ra) (Kineret; Amgen, Thousand Oaks, CA), and polyethylene glycol–conjugated soluble TNF receptor type I resulted in synergistic improvement in the symptoms of adjuvant‐induced and collagen‐induced arthritis in rats relative to the improvement observed with either agent alone (10, 11). Additive or synergistic improvement was seen with a variety of dose combinations of each agent, but synergistic improvement was particularly evident when suboptimal doses of each agent were given in combination.

The present study was designed to test the hypothesis that combination therapy with the anti‐TNF agent etanercept, a soluble TNFα receptor (Enbrel; Amgen), and the anti–IL‐1 agent anakinra at their approved dosages would safely provide superior efficacy relative to etanercept alone in patients with RA. Secondarily, the study examined the possibility that anakinra given with etanercept at a dosage of 25 mg once weekly (half the approved weekly dose) would still provide superior efficacy compared with full‐dosage etanercept alone.

PATIENTS AND METHODS

Patients

This study enrolled patients who were at least 18 years old and had a >6‐month history of RA, as diagnosed by the American College of Rheumatology (ACR) classification criteria (12). Patients had at least 6 swollen joints and 9 tender/painful joints and at least 2 of the following: morning stiffness lasting at least 45 minutes, a serum C‐reactive protein (CRP) level of at least 1.5 mg/dl, or an erythrocyte sedimentation rate (ESR) of at least 28 mm/hour. Patients had received methotrexate (MTX) for at least 16 weeks, with the dosage stable at 10–25 mg/week for at least 8 weeks. All patients gave informed consent, and the study protocol was approved by the institutional review boards for each study site.

Patients were not eligible to enroll in the study if they had received any disease‐modifying antirheumatic drug other than MTX within the past 4 weeks, had ever been treated with anakinra or any protein‐based TNFα inhibitor (e.g., etanercept, infliximab), had received any intraarticular or systemic corticosteroid injections within the past 4 weeks, or had a recent history of significant infection or other important concurrent illness.

Study design and treatment

Patients were randomly assigned in a 1:1:1 ratio to receive 25 mg of etanercept twice weekly anakinra placebo once daily, 25 mg of etanercept once weekly 100 mg of anakinra daily, or 25 mg of etanercept twice weekly 100 mg of anakinra once daily (hereafter referred to a etanercept only, half‐dosage etanercept anakinra, and full‐dosage etanercept anakinra, respectively). Both etanercept and anakinra were administered subcutaneously for 24 weeks. In order to blind patients to the treatment assignment, additional sham injections of etanercept were administered as necessary, so that all patients received twice weekly injections of etanercept/sham and once daily injections of anakinra or matched placebo. Patients continued to receive stable doses of MTX and other medications (e.g., corticosteroids) throughout the study. After screening, patients were evaluated at baseline (day 1) and at weeks 2, 4, 8, 12, 16, 20, and 24, with followup evaluation 4 weeks after completion or at the time of early discontinuation.

Endogenous human IL‐1Ra was isolated, purified, and produced by recombinant DNA technology using Escherichia coli fermentation. The resulting product, anakinra, is identical to the naturally occurring nonglycosylated form of human IL‐1Ra except for the addition of an N‐terminal methionine residue. Anakinra was provided by Amgen in single‐use vials as a liquid containing 1 ml of 100 mg/ml anakinra. The formulation consisted of sodium citrate, sodium chloride, disodium EDTA, and polysorbate 80. The placebo formulation was the same, but without anakinra. Both solutions were pH 6.5.

Etanercept is a soluble TNF receptor fusion protein produced by recombinant DNA technology in a Chinese hamster ovary mammalian cell expression system. Etanercept was supplied by Amgen in 25‐mg single‐use vials containing etanercept lyophilized powder, mannitol, sucrose, and tromethamine. After reconstitution with bacteriostatic water, the solution had a mean (±SD) pH of 7.4 ± 0.3.

Efficacy assessment

At every study visit, patients were assessed for the components of the ACR core set of disease activity measures (13), the modified Disease Activity Score (DAS) (14), the European League Against Rheumatism (EULAR) response (14), and the duration of morning stiffness. A health‐related quality‐of‐life evaluation with the Short Form 36 (SF‐36) healthy survey (15) was performed at baseline and at weeks 4, 12, and 24 (or at the time of early termination).

The primary end point was the proportion of patients achieving an ACR 50% (ACR50) response (16) at week 24. Secondary efficacy end points included the ACR20 and ACR70 response rates at week 24, the ACR response at week 12, the sustained ACR20 response (response for at least 4 monthly measurements, not necessarily consecutive, with 1 occurring at month 6), a good or moderate EULAR response at week 24, improvement in the ACR core criteria components, duration of morning stiffness, the DAS, and the SF‐36 score.

Patients were considered ACR50 responders if they had at least a 50% reduction in the number of tender and swollen joints and in 3 of the following 5 measures: patient's assessment of disease activity by visual analog scale (VAS), physician's assessment of disease activity by VAS, patient's assessment of pain by VAS, the disability score as measured by the Health Assessment Questionnaire (17), and acute‐phase reactants (CRP or ESR). The joint counts (66 joints evaluated for swelling, and 68 joints evaluated for tenderness/pain) were assessed by the same qualified independent assessors at each study center throughout the study. To preserve blinding of the study, injection sites were covered with clothing during the joint counts to insure that the assessors would not be influenced by injection‐site reactions.

Safety and pharmacokinetic assessment

Safety assessment data that were collected at every study visit were the number of adverse events/infectious events and the clinical laboratory values. An adverse event was defined as follows: “Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment” (18). A serious adverse event was defined as follows: “Any untoward medical occurrence that at any dose results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect” (18).

Blood samples were collected for measurement of plasma anakinra and etanercept concentrations (at baseline and weeks 4, 12, and 24 [or at the time of early termination]) and anti‐anakinra and anti‐etanercept antibodies (at baseline and weeks 12 and 24 [or at the time of early termination]). Plasma anakinra concentrations were assessed by antibody‐capture enzyme‐linked immunoassay (ELISA), and plasma etanercept concentrations were assessed by a solid‐phase sandwich ELISA kit. Antibody samples testing positive in a screening biosensor immunoassay (Biacore, Uppsala, Sweden) were retested for neutralizing antibodies, using a bioassay.

Statistical analysis

Results were analyzed using a modified intent‐to‐treat method that included all randomized patients who received at least 1 dose each of anakinra/placebo and etanercept/sham. Patients with missing ACR scores at a particular visit were considered nonresponders at that visit.

The primary comparison was the full‐dosage etanercept anakinra group against the etanercept‐only group. The analysis was 1‐tailed for the primary comparison and 2‐tailed for the secondary comparisons. Odds ratios (ORs) and their confidence intervals (CIs) were calculated for comparisons between groups. Binary efficacy end points were analyzed using a logistic regression model. Continuous end points were analyzed over time using a repeated‐measures mixed model.

Adverse events were tabulated for comparison across treatment groups, and summary statistics were calculated for laboratory values.

RESULTS

Characteristics of the study patients.

The baseline demographics and disease characteristics of the patients are shown in Table 1. Most of the patients were women with long‐standing and very active disease. Characteristics were balanced across treatment groups. Completion rates ranged from 78% to 93%, with the highest rate in the etanercept‐only group (Figure 1). Significantly fewer patients in this group withdrew as a result of adverse events compared with the combination‐therapy groups.

Table 1. Baseline characteristics of study patients*
Characteristic Etanercept only (n = 80) Half‐dosage etanercept + anakinra (n = 81) Full‐dosage etanercept + anakinra (n = 81)
% female 82.5 71.6 77.8
% white race 86.3 77.8 75.3
Age, years 54.4 ± 13.6 53.8 ± 11.8 55.7 ± 13.0
% age ≥ 65 years 25.0 18.5 29.6
Weight, kg 75 ± 18 82 ± 21 80 ± 23
Duration of RA, years 9.7 ± 9.4 9.5 ± 10.3 10.6 ± 9.8
% rheumatoid factor positive 65.0 75.3 71.6
% receiving corticosteroids 48.8 54.3 44.4
NSAID use, % 96.3 95.1 96.3
MTX dosage, mg/week 16.1 ± 4.5 16.2 ± 4.2 15.7 ± 5.0
No. of tender/painful joints 31.0 ± 14.2 31.0 ± 15.4 35.9 ± 14.9
No. of swollen joints 21.4 ± 9.4 19.8 ± 9.6 23.4 ± 12.0
HAQ score 1.5 ± 0.6 1.5 ± 0.6 1.6 ± 0.6
Serum CRP, mg/dl 2.0 ± 2.2 2.4 ± 3.5 2.0 ± 2.5
ESR, mm/hour 44.6 ± 21.51 49.2 ± 22.81 49.9 ± 23.94
Duration of morning stiffness, minutes 145.3 ± 102.3 154.4 ± 162.1 159.5 ± 134.0
SF‐36 score
 Physical component 28.7 ± 9.7 28.8 ± 7.9 29.1 ± 7.9
 Mental component 46.9 ± 12.3 47.9 ± 10.9 44.5 ± 11.9
  • * Except where indicated otherwise, values are the mean ± SD. Etanercept only = etanercept 25 mg twice weekly; half‐dosage etanercept + anakinra = etanercept 25 mg once weekly anakinra 100 mg daily; full‐dosage etanercept + anakinra = etanercept 25 mg twice weekly anakinra 100 mg daily; RA = rheumatoid arthritis; NSAID = nonsteroidal antiinflammatory drug; MTX = methotrexate; HAQ = Health Assessment Questionnaire; CRP = C‐reactive protein; ESR = erythrocyte sedimentation rate; SF‐36 = Short Form 36.

Disposition of patients. Other reasons for premature withdrawal included protocol violations and patients being lost to followup. BIW = twice weekly; QW = once weekly; QD = once daily.

Efficacy results.

Patients in all treatment groups showed improvement from baseline at week 24 (Figure 2). Therapy in the etanercept‐only group resulted in an ACR50 of 41%, compared with 31% in the full‐dosage etanercept anakinra group (P = 0.914, by 1‐tailed t‐test). The OR for achieving an ACR50 response in the full‐dosage etanercept anakinra group relative to that in the etanercept‐only group was 0.64 (90% CI 0.37–1.09). The OR for achieving an ACR50 response in the etanercept‐only group relative to that in the half‐dosage etanercept anakinra group was 1.11 (95% CI 0.59–2.09). For the comparison of patients in the full‐dosage (twice weekly) combination‐therapy group relative to those in the low‐dosage (once weekly) combination therapy group, the OR was 0.71 (95% CI 0.37–1.35).

Percent of patients achieving an American College of Rheumatology 20% (ACR20), ACR50, or ACR70 response at week 24. BIW = twice weekly; QW = once weekly.

Because the dropout rate was higher in the groups receiving combination therapy, it was important to determine whether this influenced the efficacy results. Sensitivity analyses, including a completers analysis (all patients who completed the study) and a last observation carried forward analysis, yielded results similar to those observed in the modified intent‐to‐treat analysis (data not shown), indicating that differential dropout rates did not influence the outcome. In addition, results were unaffected when they were adjusted for baseline covariates (data not shown).

Evaluation of the ACR20 and ACR70 response rates confirmed that combination therapy was not superior to etanercept alone. The only comparison yielding a statistically significant difference between treatments indicated that at week 24, the ACR20 response of patients treated with etanercept alone was superior to that of patients treated with etanercept once weekly anakinra (OR 1.98, 95% CI 1.05–3.78; P = 0.037).

Between 43% and 54% of patients in each treatment group achieved a sustained ACR20 response during the study, and most patients achieved a EULAR response at week 24 (79% of patients in etanercept‐only group, 73% of those in the full‐dosage etanercept anakinra group, and 66% of patients in the half‐dosage etanercept anakinra group received a good or moderate rating). At week 24, the mean percent reduction from baseline in the DAS was 39% in the etanercept‐only group, 40% in the half‐dosage etanercept anakinra group, and 41% in the full‐dosage etanercept anakinra group. Radiographs were not obtained in this study.

Pharmacokinetics.

Plasma concentrations for weeks 4, 12, and 24 indicated that the pharmacokinetic steady state was reached by week 4 for both etanercept and anakinra, and thus the data for all visits were pooled for analysis. The pharmacokinetics of each agent appeared unaffected by the concomitant administration of the other (Figures 3 and 4). Plasma concentrations of anakinra and etanercept were similar to those observed in previous studies of anakinra or etanercept alone (Genovese MC, et al: unpublished observations).

Individual plasma etanercept concentrations (Conc). Because the results at each week indicated that the pharmacokinetic steady state of etanercept was reached by week 4, the data for all visits (weeks 4, 12, and 24) were pooled for analysis. BIW = twice weekly; QW = once weekly; QD = once daily; h = hours.

Individual plasma anakinra concentrations. Because the results at each week indicated that the pharmacokinetic steady state of anakinra was reached by week 4, the data for all visits (weeks 4, 12, and 24) were pooled for analysis. See Figure 3 for definitions.

Safety.

The proportion of patients reporting adverse events was similar for each treatment group (90–95%) (Table 2). However, combination therapy with anakinra and etanercept was associated with a higher overall incidence of serious adverse events, events causing patient withdrawal from study, and injection‐site reactions.

Table 2. Incidence of adverse events during treatment*
Event Etanercept only (n = 80) Half‐dosage etanercept + anakinra (n = 81) Full‐dosage etanercept + anakinra (n = 81)
Any adverse event 72 (90.0) 77 (95.1) 76 (93.8)
Most common adverse events
 Injection‐site reaction 32 (40.0) 55 (67.9) 57 (70.4)
 Upper respiratory infection 16 (20.0) 9 (11.1) 11 (13.6)
Any adverse event causing withdrawal 0 (0) 7 (8.6) 6 (7.4)
Any serious adverse event 2 (2.5) 4 (4.9) 12 (14.8)
Any infection 32 (40.0) 30 (37.0) 38 (46.9)
 Infection resulting in antibiotic administration or hospitalization 0 (0.0) 3 (3.7) 6 (7.4)
 Infection leading to withdrawal 0 (0.0) 2 (2.5) 2 (2.5)
 Serious infection 0 (0) 3 (3.7) 6 (7.4)
  Serious pneumonia 0 (0) 1 (1.2) 2 (2.5)
  Serious cellulitis 0 (0) 1 (1.2) 2 (2.5)
  • * Values are the number (%) of patients. See Table 1 for definitions.

Serious adverse events were generally individual occurrences, with no single category of event accounting for the increase observed with combination therapy (Table 3). However, infections accounted for serious events in 9 of 16 patients receiving combination therapy. The reported serious infections were as follows: pneumonia and cellulitis (3 patients each), herpes zoster (1 patient), pneumonitis (1 patient), and pyelonephritis (1 patient). One 70‐year‐old patient with pulmonary fibrosis was diagnosed as having pneumonia and died of pulmonary insufficiency. Serious infections occurred an average of 2 months after exposure to combination treatment (range 1 week to 5 months) in patients whose mean age was 60 years (range 42–77 years). No cases of tuberculosis or opportunistic infections were reported.

Table 3. Serious adverse events that occurred during the study*
Event Etanercept only (n = 80) Half‐dosage etanercept + anakinra (n = 81) Full‐dosage etanercept + anakinra (n = 81)
Cellulitis 0 (0) 1 (1.2) 2 (2.5)
Pneumonia 0 (0) 1 (1.2) 1 (1.2)
Pneumonia and pulmonary fibrosis leading to respiratory insufficiency 0 (0) 0 (0) 1 (1.2)
Gastroenteritis 0 (0) 0 (0) 1 (1.2)
Herpes zoster 0 (0) 0 (0) 1 (1.2)
Lymphoma, malignant 0 (0) 0 (0) 1 (1.2)
Neuralgia 0 (0) 0 (0) 1 (1.2)
Back pain 0 (0) 0 (0) 1 (1.2)
Chest pain, cardiac 0 (0) 0 (0) 1 (1.2)
Chest pain, noncardiac 0 (0) 0 (0) 1 (1.2)
Pyelonephritis 0 (0) 0 (0) 1 (1.2)
Transient ischemic attack 0 (0) 0 (0) 1 (1.2)
Arrhythmia, atrial 1 (1.3) 0 (0) 0 (0)
Dyspnea 0 (0) 1 (1.2) 0 (0)
Gastric ulcer, hemorrhage 0 (0) 1 (1.2) 0 (0)
Personality disorder 1 (1.3) 0 (0) 0 (0)
Pneumonitis 0 (0) 1 (1.2) 0 (0)
  • * Values are the number (%) of patients. See Table 1 for definitions

The incidence of injection‐site reactions was more than 50% higher with combination therapy than with etanercept alone. These reactions were transient, rarely severe (a combined incidence of 2% in the combination‐therapy groups), and typically involved no clinical sequelae. However, they were the most common cause of adverse event–related withdrawal during the study for patients receiving combination therapy, accounting for 5 of 13 adverse event–related withdrawals. Injection‐site reactions were less likely to occur after the first month of therapy.

The mean neutrophil counts decreased to a similar extent in all 3 groups within the first 2 weeks of initiating treatment but remained stable thereafter. Two patients in the full‐dosage etanercept anakinra group experienced neutropenia (neutrophil count <1.0 × 109/liter) during the study. Both patients completed the study, and no clinical events were associated with the neutropenia. No subjects had changes in the neutrophil count that appeared to be associated with their serious infectious episodes. None of the subjects who experienced serious infectious episodes experienced neutropenia. No other clinically significant trends in the laboratory results were apparent. Three patients receiving anakinra and no patients receiving etanercept had evidence of potentially neutralizing anti‐anakinra and anti‐etanercept antibodies, respectively. The presence of antibodies had no apparent effect on efficacy or safety.

DISCUSSION

The clinical hypothesis for this study, that combination treatment with selective anticytokine therapies (etanercept and anakinra) would safely provide superior improvement in the signs and symptoms of RA compared with etanercept alone, proved false. Analyses of the primary efficacy end point, the ACR50 response at week 24, showed no significant differences between groups regardless of the combination regimen used (etanercept twice weekly or once weekly). In fact, patients who received etanercept only in this study had the highest ACR responses, similar to those seen in previous studies of etanercept (4, 8), and encountered the fewest safety problems.

Results of preclinical experiments suggested that simultaneous blockade of IL‐1 and TNFα would be more effective than either approach alone in inhibiting progression of RA, with a combination of suboptimal doses of each anticytokine agent providing a synergistic effect. The reasons for the discrepancy between the preclinical and clinical results are unclear, but several theories present themselves. First, there may have been a negative interaction between the compounds. This theory seems unlikely, because the pharmacokinetic results show that plasma concentrations for both agents remained unchanged relative to observations for each agent independently. Also, anakinra is eliminated renally (19-21), while etanercept is eliminated by the Kupffer cells of the liver (Genovese MC, et al: unpublished observations). It is also unlikely that anakinra and etanercept would bind and block the effect of each other.

Second, anti‐anakinra antibodies could be responsible for the lack of benefit of combination therapy. This too is unlikely, because a low percentage of patients had potentially neutralizing anti‐anakinra antibodies, and the antibody results from this study were consistent with the antibody data from other anakinra studies in which efficacy was demonstrated. Third, anti‐TNF therapy could have down‐regulated IL‐1 expression, rendering any impact of anti–IL‐1 therapy negligible. This remains a possibility, although it would not explain the inconsistency between the clinical and preclinical results. Fourth, the degree of overlap and interplay between IL‐1 and TNF may leave little room for improvement beyond the efficacy attainable with an effective TNF inhibitor. This is an intriguing possibility that requires further study.

The safety results for this study showed that combination anticytokine therapy was associated with a higher incidence of serious infections than was observed with the use of etanercept alone. These results are comparable with what was previously reported in a small open‐label study of the combination of etanercept and anakinra (22). Many patients in this study were receiving a combination of 4 potentially immunosuppressive agents, including corticosteroids, MTX, anakinra, and etanercept, all of which could have contributed to this finding. Combination therapy was also more commonly associated with neutropenia, which is probably not surprising because decreases in the neutrophil count have been associated with both etanercept and anakinra (Genovese MC, et al: unpublished observations). It is notable, however, that in this study neutropenia was not associated with the risk of serious infection.

These results suggest that use of combination treatment with anakinra and etanercept is not justified in patients with RA who are naive to biologic therapy. However, the possibility that combination anticytokine treatment could benefit certain patients cannot be excluded based on this relatively small study. The response to combination therapy might be different in patients with partial or inadequate responses to prior anticytokine treatment, for example, although the safety concerns raised by this study would remain. Furthermore, these results do not preclude the possibility of successful combination therapy with future agents selectively blocking other pathways.

Overall, the results from this study provide no evidence of an additional treatment benefit of combination therapy with etanercept anakinra in patients with active RA despite the use of MTX. In fact, the combination posed an increased risk of serious infection and neutropenia. Treatment with etanercept or anakinra alone, or either agent in combination with MTX, has been demonstrated to be effective and safe in previous studies, and the findings from this study do not affect the profiles of the individual compounds. The findings do raise important questions about the role of each of these cytokines in the pathophysiology of RA and other inflammatory diseases. The development of anticytokine therapies has epitomized the translation of research from bench to bedside, and the results of this study highlight the need to translate these results back to the bench to better understand the interrelationship of these cytokines in human disease and to explain the incongruity of the preclinical and clinical findings.

Acknowledgements

We thank Bing Bing Yang for assistance with the pharmacokinetic analyses, Thomas Liu and Tenshang Joh for assistance with the statistical analysis, and Steve Fletcher for assistance with the manuscript.

    APPENDIX A

    MEMBERS OF THE 20000223 STUDY GROUP

    Members of the 20000223 Study Group, in addition to the authors of this article, are as follows: S. Block (Bangor, ME), M. Borofsky (West Reading, PA), J. Box (Charlotte, NC), R. Brasington (St. Louis, MO), A. Brodsky (Dallas, TX), K. Bulpitt (Los Angeles, CA), J. Caldwell (Gainesville, FL), R. Coalson (Beavercreek, OH), J. Cush (Dallas, TX), A. Deadhar (Portland, OR), G. Divittorio (Mobile, AL), A. Fishman (Atlanta, GA), M. Greenwald (Rancho Mirage, CA), E. Hurd (Dallas, TX), J. Kay (Burlington, MA), A. Kavanaugh (La Jolla, CA), M. Kohen (South Daytona Beach, FL), S. Maestrello (Richmond, VA), R. Malamet (Hagerstown, MD), D. Mandel (Mayfield Village, OH), R. Martin (Grand Rapids, MI), S. Mathews (South Jacksonville, FL), M. Pearson (Brookfield, WI), J. Poiley (Orlando, FL), T. Romano (Los Angeles, CA), S. Roth (Phoenix, AZ), J. Rutstein (San Antonio, TX), M. Schiff (Denver, CO), M. Schweitz (West Palm Beach, FL), W. Shergy (Huntsville, AL), H. Staley (Indianapolis, IN), G. Sultany (Portland, OR), W. Surbeck (Tulsa, OK), J. Taborn (Kalamazoo, MI), P. Valen (La Crosse, WI), R. Valente (Lincoln, NE), D. Wallace (Los Angeles, CA), C. Weidmann (Van Nuys, CA).

      Number of times cited according to CrossRef: 283

      • , Interleukin (IL)-1 Blocking Compounds and Their Use in Autoinflammatory Diseases, Textbook of Autoinflammation, 10.1007/978-3-319-98605-0_41, (751-774), (2019).
      • , Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti‐tumour necrosis factor, Alimentary Pharmacology & Therapeutics, 47, 8, (1117-1125), (2018).
      • , Long‐term efficacy and safety of add‐on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors, International Journal of Rheumatic Diseases, 21, 3, (673-687), (2018).
      • , Phase II Study of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate, Arthritis & Rheumatology, 70, 11, (1778-1789), (2018).
      • , Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review, Expert Opinion on Biological Therapy, 10.1080/14712598.2018.1492545, 18, 7, (821-827), (2018).
      • , Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders, Clinical Gastroenterology and Hepatology, 10.1016/j.cgh.2018.02.024, (2018).
      • , Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review, Advances in Therapy, 10.1007/s12325-018-0757-2, 35, 10, (1535-1563), (2018).
      • , New and emerging concepts in the use of denosumab for the treatment of osteoporosis, Therapeutic Advances in Musculoskeletal Disease, 10.1177/1759720X18805759, 10, 11, (209-223), (2018).
      • , New treatment paradigms in spondyloarthritis, Current Opinion in Rheumatology, 10.1097/BOR.0000000000000457, 30, 1, (79-86), (2018).
      • , Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting, The Journal of Rheumatology, 10.3899/jrheum.161270, 45, 2, (170-176), (2017).
      • , ABT‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate, Arthritis & Rheumatology, 70, 11, (1710-1720), (2018).
      • , Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis, Rheumatology International, 10.1007/s00296-018-4041-1, 38, 8, (1363-1383), (2018).
      • , Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: a systematic review and meta-analysis, Seminars in Arthritis and Rheumatism, 10.1016/j.semarthrit.2018.12.003, (2018).
      • , Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies, Autoimmunity Reviews, 10.1016/j.autrev.2018.07.014, (2018).
      • , The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation, Science Signaling, 10.1126/scisignal.aah4273, 10, 475, (eaah4273), (2017).
      • , Confounding role of tumor necrosis factor in cryopyrin-associated periodic syndromes, Journal of Clinical Investigation, 10.1172/JCI98322, (2017)., (2017).
      • , Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry), Expert Opinion on Drug Safety, 10.1080/14740338.2017.1372421, 16, 11, (1255-1271), (2017).
      • , Medicinal Chemistry Case History: Structure-Based Drug Design of Oral and Inhaled p38 MAP Kinase Inhibitors as Clinical Candidates, Comprehensive Medicinal Chemistry III, 10.1016/B978-0-12-409547-2.12458-8, (408-430), (2017).
      • , Anti-cytokine Therapies, Kelley and Firestein's Textbook of Rheumatology, 10.1016/B978-0-323-31696-5.00063-2, (999-1019), (2017).
      • , Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature, Clinical Rheumatology, 10.1007/s10067-017-3722-6, 36, 8, (1699-1706), (2017).
      • , Etiology and Pathogenesis of Rheumatoid Arthritis, Kelley and Firestein's Textbook of Rheumatology, 10.1016/B978-0-323-31696-5.00069-3, (1115-1166.e7), (2017).
      • , TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies, Journal of Clinical Investigation, 10.1172/JCI90699, (2017)., (2017).
      • , Bispecific Antibodies, Next-Generation Therapies and Technologies for Immune-Mediated Inflammatory Diseases, 10.1007/978-3-319-42252-7_5, (75-97), (2017).
      • , Treatment of Rheumatoid Arthritis, Kelley and Firestein's Textbook of Rheumatology, 10.1016/B978-0-323-31696-5.00071-1, (1187-1212.e5), (2017).
      • , Selected cytokine pathways in rheumatoid arthritis, Seminars in Immunopathology, 10.1007/s00281-017-0619-z, 39, 4, (365-383), (2017).
      • , Therapeutic Applications: Strategies and Molecules Targeting the IL-17/Th17 Pathway, Targeting the IL-17 Pathway in Inflammatory Disorders, 10.1007/978-3-319-28040-0_5, (55-99), (2016).
      • , Metalloproteinases in Rheumatoid Arthritis: Potential Therapeutic Targets to Improve Current Therapies, Matrix Metalloproteinases and Tissue Remodeling in Health and Disease: Target Tissues and Therapy, 10.1016/bs.pmbts.2017.03.002, (327-338), (2017).
      • , Safety, Tolerability, and Pharmacodynamics of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17–Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis, Arthritis & Rheumatology, 69, 12, (2283-2291), (2017).
      • , Combination of antitumour necrosis factor‐α and anti‐interleukin‐12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long‐term case‐series observational study, British Journal of Dermatology, 174, 5, (1145-1146), (2016).
      • , Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases, mAbs, 10.1080/19420862.2015.1093266, 8, 1, (141-149), (2015).
      • , A revolutionary therapeutic approach for psoriasis: bispecific biological agents, Expert Opinion on Investigational Drugs, 10.1080/13543784.2016.1187130, 25, 7, (751-754), (2016).
      • , Making anti-cytokine therapy more selective: Studies in mice, Cytokine, 10.1016/j.cyto.2016.08.022, (2016).
      • , Etanercept, Therapy for Severe Psoriasis, 10.1016/B978-0-323-44797-3.00008-6, (83-96), (2016).
      • , Other Biological Therapies for Pediatric Rheumatic Diseases, Pediatrics in Systemic Autoimmune Diseases, 10.1016/B978-0-444-63596-9.00024-4, (503-525), (2016).
      • , Bifunctional role of pro-inflammatory cytokines after traumatic brain injury, Brain Injury, 10.3109/02699052.2016.1163618, 30, 9, (1043-1053), (2016).
      • , Cell cycle regulation therapy combined with cytokine blockade enhances antiarthritic effects without increasing immune suppression, Annals of the Rheumatic Diseases, 10.1136/annrheumdis-2014-205566, 75, 1, (253-259), (2014).
      • , Selective Inhibition of Membrane Type 1 Matrix Metalloproteinase Abrogates Progression of Experimental Inflammatory Arthritis: Synergy With Tumor Necrosis Factor Blockade, Arthritis & Rheumatology, 68, 2, (521-531), (2016).
      • , Alterations in immune function with biologic therapies for autoimmune disease, Journal of Allergy and Clinical Immunology, 10.1016/j.jaci.2015.10.023, 137, 1, (19-27), (2016).
      • , Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies, Current Rheumatology Reports, 10.1007/s11926-016-0609-5, 18, 10, (2016).
      • , Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions, Drug Discovery Today, 10.1016/j.drudis.2015.10.012, 21, 1, (180-189), (2016).
      • , Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial, Modern Rheumatology, 10.3109/14397595.2016.1160968, 26, 6, (900-907), (2016).
      • , Combination therapy with biologic agents in rheumatic diseases: current and future prospects, Therapeutic Advances in Musculoskeletal Disease, 10.1177/1759720X16665330, 8, 5, (192-202), (2016).
      • , Pharmacology, Textbook of Pediatric Rheumatology, 10.1016/B978-0-323-24145-8.00013-2, (161-175.e6), (2016).
      • , Adalimumab, Therapy for Severe Psoriasis, 10.1016/B978-0-323-44797-3.00010-4, (111-126), (2016).
      • , Perspectives From Masters in Rheumatology and Autoimmunity: Can We Get Closer to a Cure for Rheumatoid Arthritis?, Arthritis & Rheumatology, 67, 9, (2283-2291), (2015).
      • , Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, Rheumatology, 10.1093/rheumatology/keu461, 54, 7, (1200-1209), (2014).
      • , Risk of Hospitalized Infection Among Rheumatoid Arthritis Patients Concurrently Treated With a Biologic Agent and Denosumab, Arthritis & Rheumatology, 67, 6, (1456-1464), (2015).
      • , Combination therapy with TNFR-Fc and CTLA4-FasL using the recombinant adeno-associated virus potently suppresses adjuvant-induced arthritis in rats, Applied Microbiology and Biotechnology, 10.1007/s00253-015-6459-7, 99, 15, (6327-6337), (2015).
      • , Therapeutic targets in psoriatic arthritis, International Journal of Clinical Rheumatology, 10.2217/ijr.15.52, 10, 6, (489-499), (2015).
      • , Evasion of inflammasome activation by microbial pathogens, Journal of Clinical Investigation, 10.1172/JCI75254, 125, 2, (469-477), (2015).
      • , Novel therapeutic targets in rheumatoid arthritis, Trends in Pharmacological Sciences, 10.1016/j.tips.2015.02.001, 36, 4, (189-195), (2015).
      • , Co-morbidity index in rheumatoid arthritis: time to think, Clinical Rheumatology, 10.1007/s10067-015-3101-0, 34, 12, (1995-2000), (2015).
      • , Perioperative Treatment of Patients with Rheumatoid Arthritis, Journal of the American Academy of Orthopaedic Surgeons, 10.5435/JAAOS-D-15-00014, 23, 9, (e38-e48), (2015).
      • , Anti-TNF therapy: past, present and future, International Immunology, 10.1093/intimm/dxu102, 27, 1, (55-62), (2014).
      • , Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease, Autoimmunity Reviews, 10.1016/j.autrev.2014.08.008, 14, 1, (1-9), (2015).
      • , Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis, Best Practice & Research Clinical Rheumatology, 10.1016/j.berh.2015.05.009, 29, 2, (290-305), (2015).
      • , Combined Inhibition of Tumor Necrosis Factor α and Interleukin‐17 As a Therapeutic Opportunity in Rheumatoid Arthritis: Development and Characterization of a Novel Bispecific Antibody, Arthritis & Rheumatology, 67, 1, (51-62), (2014).
      • , Optimized Nonclinical Safety Assessment Strategies Supporting Clinical Development of Therapeutic Monoclonal Antibodies Targeting Inflammatory Diseases, Drug Development Research, 75, 3, (115-161), (2014).
      • , Biologic agents for rheumatoid arthritis: Can we hypothesize new strategies of treatment?, Medical Hypotheses, 10.1016/j.mehy.2013.08.028, 82, 1, (117-121), (2014).
      • , Dual Inhibition of Interleukin-1β and Interleukin-18: A New Treatment Option for Sepsis?, American Journal of Respiratory and Critical Care Medicine, 10.1164/rccm.201312-2292ED, 189, 3, (242-244), (2014).
      • , Therapeutic advancements in juvenile idiopathic arthritis, Best Practice & Research Clinical Rheumatology, 10.1016/j.berh.2014.03.005, 28, 2, (293-313), (2014).
      • , Adalimumab, Moderate to Severe Psoriasis, Fourth Edition, 10.1201/b16633-13, (199-216), (2014).
      • , Infection risk and biologics, Current Opinion in Rheumatology, 10.1097/BOR.0000000000000072, 26, 4, (404-409), (2014).
      • , Emerging immunotherapies for rheumatoid arthritis, Human Vaccines & Immunotherapeutics, 10.4161/hv.27910, 10, 4, (822-837), (2014).
      • , Effect of Cytokines on Osteoclast Formation and Bone Resorption during Mechanical Force Loading of the Periodontal Membrane, The Scientific World Journal, 10.1155/2014/617032, 2014, (1-7), (2014).
      • , The Comparative Safety of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-analysis Update of 44 Trials, The American Journal of Medicine, 10.1016/j.amjmed.2014.06.012, 127, 12, (1208-1232), (2014).
      • , Immune Compromise Associated with Biologics, Stiehm's Immune Deficiencies, 10.1016/B978-0-12-405546-9.00049-2, (889-906), (2014).
      • , Novel Mechanisms of Action of the Biologicals in Rheumatic Diseases, Clinical Reviews in Allergy & Immunology, 10.1007/s12016-013-8359-x, 47, 1, (6-16), (2013).
      • , Antibody-mediated delivery of interleukin 4 to the neo-vasculature reduces chronic skin inflammation, Journal of Dermatological Science, 10.1016/j.jdermsci.2014.07.012, 76, 2, (96-103), (2014).
      • , A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti–Interleukin‐17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors, Arthritis & Rheumatology, 66, 7, (1693-1704), (2014).
      • , Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse, Arthritis Research & Therapy, 10.1186/ar4319, 15, 5, (R138), (2013).
      • , Medikamentöse Prophylaxe während intensivierter Immunsuppression bei Kindern und JugendlichenMedicinal prophylaxis during intensified immunosuppression in children and adolescents, Zeitschrift für Rheumatologie, 10.1007/s00393-013-1203-0, 72, 9, (896-909), (2013).
      • , Kombination von BiologikaCombination of biologics, Zeitschrift für Rheumatologie, 10.1007/s00393-013-1141-x, 72, 9, (878-884), (2013).
      • , Vorsorgeuntersuchungen während intensivierter Immunsuppression bei Kindern und JugendlichenScreening investigations during intensified immunosuppression in children and adolescents, Zeitschrift für Rheumatologie, 10.1007/s00393-013-1200-3, 72, 8, (814-821), (2013).
      • , A Novel Bifunctional Protein TNFR2-Fc-IL-1ra (TFI): Expression, Purification and its Neutralization Activity of Inflammatory Factors, Molecular Biotechnology, 10.1007/s12033-012-9550-7, 54, 2, (141-147), (2012).
      • , Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples, Annals of the Rheumatic Diseases, 10.1136/annrheumdis-2013-203261, 72, 9, (1433-1435), (2013).
      • , Synergistic effect of the l-tryptophan and kynurenic acid with dipyrone or paracetamol in mice, Chemico-Biological Interactions, 10.1016/j.cbi.2013.07.005, 205, 2, (148-156), (2013).
      • , Anticytokine Therapies, Kelley's Textbook of Rheumatology, 10.1016/B978-1-4377-1738-9.00063-3, (957-977.e4), (2013).
      • , Treatment of Rheumatoid Arthritis, Kelley's Textbook of Rheumatology, 10.1016/B978-1-4377-1738-9.00071-2, (1137-1160.e4), (2013).
      • , Monoclonal antibody treatments for rheumatoid arthritis, Expert Opinion on Biological Therapy, 10.1517/14712598.2013.811230, 13, 9, (1257-1272), (2013).
      • , Guidelines for the drug treatment of rheumatoid arthritis, Revista Brasileira de Reumatologia (English Edition), 10.1016/S2255-5021(13)70020-8, 53, 2, (158-183), (2013).
      • , Diretrizes para o tratamento da artrite reumatoide, Revista Brasileira de Reumatologia, 10.1590/S0482-50042013000200004, 53, 2, (158-183), (2013).
      • , Design, expression and characterization of a novel coexpression system of two antiarthritic molecules, Applied Microbiology and Biotechnology, 10.1007/s00253-013-4787-z, 97, 14, (6301-6314), (2013).
      • , Monoclonal antibodies in rheumatoid arthritis, International Journal of Clinical Rheumatology, 10.2217/ijr.13.52, 8, 5, (541-556), (2013).
      • , Etiology and Pathogenesis of Rheumatoid Arthritis, Kelley's Textbook of Rheumatology, 10.1016/B978-1-4377-1738-9.00069-4, (1059-1108.e5), (2013).
      • , Safety of Rituximab in Combination with Other Biologic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: An Open-label Study, The Journal of Rheumatology, 10.3899/jrheum.120924, 40, 5, (599-604), (2013).
      • , Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program, The Journal of Rheumatology, 10.3899/jrheum.120906, 40, 6, (787-797), (2013).
      • , Anakinra Potentiates the Protective Effects of Etanercept in Transplantation of Marginal Mass Human Islets in Immunodeficient Mice, American Journal of Transplantation, 12, 2, (322-329), (2011).
      • , Antigen‐specific blocking of CD4‐Specific immunological synapse formation using BPI and current therapies for autoimmune diseases, Medicinal Research Reviews, 32, 4, (727-764), (2011).
      • , Safety and tolerability of the T‐cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation, Clinical Transplantation, 26, 5, (E471-E484), (2012).
      • , Efficacy of low-dose etanercept (25mg/week): How much do we know?, Joint Bone Spine, 10.1016/j.jbspin.2012.02.008, 79, 4, (335-337), (2012).
      • , Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis, mAbs, 10.4161/mabs.21227, 4, 5, (600-613), (2014).
      • , Biologika 2012Biologicals 2012, Der Orthopäde, 10.1007/s00132-012-1931-x, 41, 7, (526-532), (2012).
      • , Effective treatment of rat adjuvant-induced arthritis by celastrol, Autoimmunity Reviews, 10.1016/j.autrev.2012.02.022, 11, 12, (856-862), (2012).
      • , Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1β signaling and a poor clinical response, Rheumatology International, 10.1007/s00296-011-1854-6, 32, 5, (1397-1401), (2011).
      • , Etanercept: efficacy and safety for approved indications, Expert Opinion on Drug Safety, 10.1517/14740338.2012.633509, 11, 1, (121-139), (2011).
      • , Combination Biologic Treatment of Refractory Psoriasis and Psoriatic Arthritis, The Journal of Rheumatology, 10.3899/jrheum.110295, 39, 1, (187.2-193), (2012).
      • , Impact of inflammation on the osteoarthritic niche: implications for regenerative medicine, Regenerative Medicine, 10.2217/rme.12.34, 7, 4, (551-570), (2012).
      • , Infections and Biologic Therapy in Rheumatoid Arthritis, Rheumatic Disease Clinics of North America, 10.1016/j.rdc.2012.08.019, 38, 4, (727-745), (2012).
      • , Rheumatoid arthritis and the era of biologic therapy, Inflammopharmacology, 10.1007/s10787-012-0123-y, 20, 2, (59-69), (2012).
      • , Biologics, Chronic Inflammation, 10.1201/b12696-30, (369-390), (2012).
      • , Infections in biological agents used in rheumatic disease, British Journal of Hospital Medicine, 73, 9, (517), (2012).
      • , PHARMACOLOGY AND DRUG THERAPY, Textbook of Pediatric Rheumatology, 10.1016/B978-1-4160-6581-4.10006-8, (71-126), (2011).
      • , NF-κB and STAT3 signaling hubs for lung innate immunity, Cell and Tissue Research, 10.1007/s00441-010-1044-y, 343, 1, (153-165), (2010).
      • , Infections and biologic therapy in rheumatoid arthritis, Rheumatology, 10.1016/B978-0-323-06551-1.00064-6, (605-610.e2), (2011).
      • , Management of rheumatoid arthritis, Rheumatology, 10.1016/B978-0-323-06551-1.00094-4, (955-963.e2), (2011).
      • , Treatment options with biologics for juvenile idiopathic arthritis, International Journal of Clinical Rheumatology, 10.2217/ijr.11.26, 6, 3, (305-323), (2011).
      • , AAPS Workshop Report: Strategies to Address Therapeutic Protein–Drug Interactions during Clinical Development, The AAPS Journal, 10.1208/s12248-011-9285-6, 13, 3, (405-416), (2011).
      • , Tumor necrosis factor blocking therapies, Rheumatology, 10.1016/B978-0-323-06551-1.00061-0, (577-596.e3), (2011).
      • , Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis, Clinical Rheumatology, 10.1007/s10067-010-1654-5, 30, 5, (697-701), (2011).
      • , Cytokine neutralizers, Rheumatology, 10.1016/B978-0-323-06551-1.00060-9, (571-576.e2), (2011).
      • , Human epidermal growth factor receptor bispecific ligand trap RB200: abrogation of collagen-induced arthritis in combination with tumour necrosis factor blockade, Arthritis Research & Therapy, 10.1186/ar3480, 13, 5, (R161), (2011).
      • , Biologics, Arthritis, 10.1201/b10852-15, (147-163), (2011).
      • , IL-1β-driven neutrophilia preserves antibacterial defense in the absence of the kinase IKKβ, Nature Immunology, 10.1038/ni.1976, 12, 2, (144-150), (2010).
      • , Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA, Current Medical Research and Opinion, 10.1185/03007995.2010.542135, 27, 2, (315-325), (2010).
      • , Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept, Scandinavian Journal of Rheumatology, 10.3109/03009742.2010.509102, 40, 3, (183-191), (2010).
      • , Biomarkers and immunomodulation as a treatment option for chronic pain conditions, Pain Management, 10.2217/pmt.10.3, 1, 1, (81-86), (2011).
      • , TNF alpha antagonist therapy and safety monitoring, Joint Bone Spine, 10.1016/S1297-319X(11)70001-X, 78, (15-185), (2011).
      • , 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features, Arthritis Care & Research, 63, 4, (465-482), (2011).
      • , The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials, Journal of the American Academy of Dermatology, 10.1016/j.jaad.2010.09.734, 64, 6, (1035-1050), (2011).
      • , Immunomodulation in perioperative medicine, Pain Management, 10.2217/pmt.11.5, 1, 2, (103-106), (2011).
      • , Shared Experiences and Best Practices in the Management of Rheumatoid Arthritis and Crohn's Disease, The American Journal of Medicine, 10.1016/j.amjmed.2011.01.001, 124, 4, (e1-e18), (2011).
      • , Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis, British Journal of Pharmacology, 162, 7, (1470-1484), (2011).
      • , Combination Therapy of Abatacept and Anakinra in Children with Refractory Systemic Juvenile Idiopathic Arthritis: A Retrospective Case Series: Table 1., The Journal of Rheumatology, 10.3899/jrheum.100726, 38, 1, (180-181), (2011).
      • , Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial, Arthritis & Rheumatism, 63, 3, (622-632), (2011).
      • , The role of synovial macrophages and macrophage‐produced mediators in driving inflammatory and destructive responses in osteoarthritis, Arthritis & Rheumatism, 62, 3, (647-657), (2010).
      • , Bone Damage in Rheumatoid Arthritis: Mechanistic Insights and Approaches to Prevention, Rheumatic Disease Clinics of North America, 10.1016/j.rdc.2010.03.003, 36, 2, (385-404), (2010).
      • , Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome, European Journal of Internal Medicine, 10.1016/j.ejim.2010.03.005, 21, 3, (157-163), (2010).
      • , IL-1 pathways in inflammation and human diseases, Nature Reviews Rheumatology, 10.1038/nrrheum.2010.4, 6, 4, (232-241), (2010).
      • , Medical treatment of rheumatoid arthritis (II): current biologic agents and newly developing drugs, Journal of the Korean Medical Association, 10.5124/jkma.2010.53.10.880, 53, 10, (880), (2010).
      • , Rheumatoid arthritis therapy: Advances from bench to bedside, Autoimmunity, 10.3109/08916931003674717, 43, 7, (478-492), (2010).
      • , IL-1-AntagonistenIL-1 antagonists, Zeitschrift für Rheumatologie, 10.1007/s00393-009-0530-7, 69, 7, (581-593), (2010).
      • , Combining Traditional Systemic and Biologic Therapies for Psoriasis, Seminars in Cutaneous Medicine and Surgery, 10.1016/j.sder.2010.03.003, 29, 1, (67-69), (2010).
      • , Clinically validated approaches to the treatment of autoimmune diseases, Expert Opinion on Investigational Drugs, 10.1517/13543780903418452, 19, 2, (195-213), (2010).
      • , Perioperative management of immunosuppression in rheumatic diseases—what to do?, Rheumatology International, 10.1007/s00296-009-1323-7, 30, 8, (999-1004), (2009).
      • , Infektionskomplikationen unter Biologika-Therapie bei Patienten mit rheumatoider ArthritisInfectious complications of biologic therapy in patients with rheumatoid arthritis, Zeitschrift für Rheumatologie, 10.1007/s00393-010-0677-2, 69, 10, (879-888), (2010).
      • , The Role of Interleukin-1 in Wound Biology. Part II, Anesthesia & Analgesia, 10.1213/ANE.0b013e3181f691eb, 111, 6, (1534-1542), (2010).
      • , Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy, Clinical Rheumatology, 10.1007/s10067-009-1338-1, 29, 3, (233-239), (2009).
      • , Optimising the strategy of care in early rheumatoid arthritis, Best Practice & Research Clinical Rheumatology, 10.1016/j.berh.2009.11.009, 24, 4, (443-455), (2010).
      • , Angiogenesis in joint disease: the need for clinical data, International Journal of Clinical Rheumatology, 10.2217/ijr.10.41, 5, 4, (439-449), (2010).
      • , Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade, Rheumatology International, 10.1007/s00296-009-1191-1, 30, 12, (1571-1580), (2009).
      • , Elevated GM-CSF and IL-1β levels compromise the ability of p38 MAPK inhibitors to modulate TNFα levels in the human monocytic/macrophage U937 cell line, Molecular BioSystems, 10.1039/c002848g, 6, 10, (1956), (2010).
      • , The Balancing Act of Autoimmunity: Central and Peripheral Tolerance Versus Infection Control, International Reviews of Immunology, 10.3109/08830180903434219, 29, 2, (211-233), (2010).
      • , Elective surgery in rheumatic disease and immunosuppression: to pause or not, Rheumatology, 10.1093/rheumatology/keq049, 49, 10, (1799-1800), (2010).
      • , Strategies after the failure of the first anti-tumor necrosis factor α agent in rheumatoid arthritis, Autoimmunity Reviews, 10.1016/j.autrev.2010.04.002, 9, 8, (574-582), (2010).
      • , ET-Kyoto Ductal Injection and Density-Adjusted Purification Combined With Potent Anti-Inflammatory Strategy Facilitated Single-Donor Islet Transplantation: Case Reports, Transplantation Proceedings, 10.1016/j.transproceed.2010.05.096, 42, 6, (2159-2161), (2010).
      • , Pharmacokinetic and Pharmacodynamic‐Based Drug Interactions for Therapeutic Proteins, Pharmaceutical Sciences Encyclopedia, (1-34), (2013).
      • , Drug–Drug Interactions for Etanercept—A Fusion Protein, Pharmaceutical Sciences Encyclopedia, (1-8), (2013).
      • , Assessing infection risk with biologic agents in RA: methodological challenges, Nature Reviews Rheumatology, 10.1038/nrrheum.2009.51, 5, 5, (288-291), (2009).
      • , Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab, Seminars in Arthritis and Rheumatism, 10.1016/j.semarthrit.2008.01.001, 38, 4, (265-280), (2009).
      • , IL-1 Inhibitors in the Treatment of Rheumatoid Arthritis, Rheumatoid Arthritis, 10.1016/B978-032305475-1.50047-1, (350-355), (2009).
      • , Guidelines for the Use of Conventional and Newer Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis, Drugs & Aging, 10.2165/00002512-200926040-00001, 26, 4, (273-293), (2009).
      • , Indications de l’anakinra, La Presse Médicale, 10.1016/j.lpm.2009.01.012, 38, 5, (799-807), (2009).
      • , Anakinra for Rheumatoid Arthritis: A Systematic Review, The Journal of Rheumatology, 10.3899/jrheum.090074, 36, 6, (1118-1125), (2009).
      • , Gene-expression profiling in rheumatic disease: tools and therapeutic potential, Nature Reviews Rheumatology, 10.1038/nrrheum.2009.50, 5, 5, (257-265), (2009).
      • , Cytokines and Cytokine Profiles in Human Autoimmune Diseases and Animal Models of Autoimmunity, Mediators of Inflammation, 10.1155/2009/979258, 2009, (1-20), (2009).
      • , Biologic Therapy for Rheumatoid Arthritis, BioDrugs, 10.2165/00063030-200923020-00004, 23, 2, (111-124), (2009).
      • , An M-CSF Receptor c-Fms Antibody Inhibits Mechanical Stress–Induced Root Resorption during Orthodontic Tooth Movement in Mice, The Angle Orthodontist, 10.2319/080708-412.1, 79, 5, (835-841), (2009).
      • 2009 2nd International Conference on Biomedical Engineering and Informatics Tianjin, China 2009 2nd International Conference on Biomedical Engineering and Informatics IEEE , (2009). 978-1-4244-4132-7 The Predictive Role of Symptoms/signs on ACR20 Responses in Rheumatoid Arthritis Analyzed with Data Mining Approaches , (2009). 1 8 5302485 , 10.1109/BMEI.2009.5302485 http://ieeexplore.ieee.org/document/5302485/
      • , Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS), Expert Opinion on Biological Therapy, 10.1517/14712590902875518, 9, 4, (519-531), (2009).
      • , Review of Biologic Therapies, Neuro-Ophthalmology, 10.3109/01658100903360064, 33, 6, (286-299), (2009).
      • , Incidence and nature of infectious disease in patients treated with anti-TNF agents, Autoimmunity Reviews, 10.1016/j.autrev.2009.08.006, 9, 2, (67-81), (2009).
      • , Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis, Nature Reviews Rheumatology, 10.1038/nrrheum.2009.181, 5, 10, (578-582), (2009).
      • , Severe Refractory Rheumatoid Arthritis Successfully Treated with Combination Rituximab and Anti-Tumor Necrosis Factor-α-Blocking Agents, The Journal of Rheumatology, 10.3899/jrheum.090160, 36, 9, (2125.2-2126), (2009).
      • , Practical Aspects of Prescribing a Biologic, Journal of Cutaneous Medicine and Surgery, 13, 5_suppl, (S93), (2009).
      • , Biologic treatments for systemic rheumatic diseases, Oral Diseases, 14, 3, (206-216), (2008).
      • , IL‐1, IL‐18, and IL‐33 families of cytokines, Immunological Reviews, 223, 1, (20-38), (2008).
      • , Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: A systematic review, Arthritis Care & Research, 59, 11, (1625-1638), (2008).
      • , How the study of children with rheumatic diseases identified interferon‐α and interleukin‐1 as novel therapeutic targets, Immunological Reviews, 223, 1, (39-59), (2008).
      • , Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics, Immunological Reviews, 223, 1, (7-19), (2008).
      • , Symptom Combinations Assessed in Traditional Chinese Medicine and Its Predictive Role in ACR20 Efficacy Response in Rheumatoid Arthritis, The American Journal of Chinese Medicine, 10.1142/S0192415X08006144, 36, 04, (675-683), (2008).
      • , The evolution of biomarkers in rheumatoid arthritis: From clinical research to clinical care, Expert Opinion on Biological Therapy, 10.1517/14712598.8.11.1773, 8, 11, (1773-1785), (2008).
      • , The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis, Current Opinion in Internal Medicine, 10.1097/MCI.0b013e328303e7c3, 7, 3, (301-307), (2008).
      • , American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis, Arthritis Care & Research, 59, 6, (762-784), (2008).
      • , Targeted therapy in rheumatoid arthritis, Expert Opinion on Drug Discovery, 10.1517/17460441.3.3.329, 3, 3, (329-342), (2008).
      • , The development of targeted therapies in rheumatoid arthritis, Journal of Autoimmunity, 10.1016/j.jaut.2008.04.006, 31, 3, (219-227), (2008).
      • , Inflammation and Cardiovascular Disease, Circulation, 10.1161/CIRCULATIONAHA.108.772491, 117, 20, (2577-2579), (2008).
      • , Differential effect on symptoms treated with traditional Chinese medicine and western combination therapy in RA patients, Complementary Therapies in Medicine, 10.1016/j.ctim.2007.08.005, 16, 4, (206-211), (2008).
      • , The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis, Current Opinion in Rheumatology, 10.1097/BOR.0b013e3282f4b392, 20, 2, (138-144), (2008).
      • , The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis, Expert Opinion on Investigational Drugs, 10.1517/13543784.17.3.349, 17, 3, (349-359), (2008).
      • , Adalimumab in the Treatment of Psoriasis, Moderate-to-Severe Psoriasis, Third Edition, 10.3109/9781420088687-14, (273-288), (2013).
      • , Abatacept in biologic-naive patients and TNF inadequate responders: clinical data in focus, Current Medical Research and Opinion, 10.1185/03007990802223129, 24, 8, (2283-2294), (2008).
      • , Dawn of the era of biologics in the treatment of the rheumatic diseases, Arthritis & Rheumatism, 58, S2, (S75-S78), (2008).
      • , Rheumatoid Arthritis, Drugs, 10.2165/00003495-200868050-00003, 68, 5, (591-606), (2008).
      • , At the horizon of innovative therapy in rheumatology: new biologic agents, Current Opinion in Rheumatology, 10.1097/BOR.0b013e3282fa13b4, 20, 3, (269-275), (2008).
      • , Tratamiento de la artritis reumatoide con anakinra: revisión sistemática, Reumatología Clínica, 10.1016/S1699-258X(07)73613-6, 3, 4, (153-158), (2007).
      • , Tumor necrosis factor as a therapeutic target of rheumatologic disease, Expert Opinion on Therapeutic Targets, 10.1517/14728222.11.11.1369, 11, 11, (1369-1384), (2007).
      • , Update on Therapeutic Monoclonal Antibodies, Current Problems in Pediatric and Adolescent Health Care, 10.1016/j.cppeds.2007.02.001, 37, 4, (118-135), (2007).
      • , Arbre décisionnel permettant le choix en pratique clinique d'un traitement de fond de seconde intention au cours de la polyarthrite rhumatoïde récente, après échec d'un traitement de fond de première intention d'une durée de six mois, Revue du Rhumatisme, 10.1016/j.rhum.2006.11.001, 74, 1, (79-84), (2007).
      • , Traitement par etanercept des polyarthrites rhumatoïdes et des spondylarthropathies à la posologie de 25 mg par semaine, Revue du Rhumatisme, 10.1016/j.rhum.2006.03.025, 74, 3, (237-241), (2007).
      • , Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases, Current Opinion in Pharmacology, 10.1016/j.coph.2007.06.001, 7, 4, (412-417), (2007).
      • , Practical Considerations for the Initiation and Maintenance of Etanercept in the Treatment of Psoriasis, Journal of Cutaneous Medicine and Surgery, 10.2310/7750.2006.00072, 11, 2_suppl, (S37-S47), (2016).
      • , Treatment of Rheumatoid Arthritis With Anakinra: A Systematic Review, Reumatología Clínica (English Edition), 10.1016/S2173-5743(07)70237-X, 3, 4, (153-158), (2007).
      • , Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6months' first-line DMARD therapy, Joint Bone Spine, 10.1016/j.jbspin.2006.05.008, 74, 1, (73-78), (2007).
      • , Mechanism of Action, Pharmacokinetics, and Drug Interactions of Etanercept in Dermatology, Journal of Cutaneous Medicine and Surgery, 10.2310/7750.2006.00069, 11, 2_suppl, (S3-S13), (2016).
      • , Complications and Adverse Reactions in the Use of Newer Biologic Agents, Seminars in Cutaneous Medicine and Surgery, 10.1016/j.sder.2006.12.002, 26, 1, (6-14), (2007).
      • , 25mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy, Joint Bone Spine, 10.1016/j.jbspin.2006.03.010, 74, 2, (144-147), (2007).
      • , Anakinra in the treatment of rheumatoid arthritis and other IL-1-driven conditions, Future Rheumatology, 10.2217/17460816.2.4.353, 2, 4, (353-360), (2007).
      • , Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis, Expert Opinion on Pharmacotherapy, 10.1517/14656566.8.9.1373, 8, 9, (1373-1397), (2007).
      • , Interleukin-1 in Rheumatoid Arthritis: Its Inhibition by IL-1Ra and Anakinra, Journal of Pharmacy Technology, 10.1177/875512250702300205, 23, 2, (86-94), (2016).
      • , Infliximab in psoriatic arthritis, Future Rheumatology, 10.2217/17460816.2.1.13, 2, 1, (13-22), (2007).
      • , Quelle est la place actuelle de l'IL-1Ra dans les maladies rhumatismales?, Revue du Rhumatisme, 10.1016/j.rhum.2006.10.670, 74, 5, (435-439), (2007).
      • , The future of TNF-α antagonism, Future Rheumatology, 10.2217/17460816.2.3.233, 2, 3, (233-236), (2007).
      • , Specificity and selectivity evaluations of ligand binding assay of protein therapeutics against concomitant drugs and related endogenous proteins, The AAPS Journal, 10.1208/aapsj0902018, 9, 2, (E164-E170), (2007).
      • , Biologic therapies in rheumatology: lessons learned, future directions, Nature Reviews Drug Discovery, 10.1038/nrd2196, 6, 1, (75-92), (2007).
      • , What is the role for interleukin-1 receptor antagonist in rheumatic disease?, Joint Bone Spine, 10.1016/j.jbspin.2006.10.006, 74, 3, (223-226), (2007).
      • , Review of Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis, The Journal of the Korean Rheumatism Association, 10.4078/jkra.2007.14.1.1, 14, 1, (1), (2007).
      • , Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges, Clinical Rheumatology, 10.1007/s10067-006-0415-y, 26, 9, (1527-1529), (2006).
      • , Clinical Pharmacokinetics and Use??of??Infliximab, Clinical Pharmacokinetics, 10.2165/00003088-200746080-00002, 46, 8, (645-660), (2007).
      • , Targets of anticytokine therapy and the risk of infections in humans and mice, Current Opinion in Rheumatology, 10.1097/BOR.0b013e3282f05c6d, 19, 6, (626-635), (2007).
      • , Abatacept: A novel therapy approved for the treatment of patients with rheumatoid arthritis, Advances in Therapy, 10.1007/BF02849902, 24, 2, (333-345), (2007).
      • , Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease‐modifying antirheumatic drugs: A one‐year randomized, placebo‐controlled study, Arthritis & Rheumatism, 54, 9, (2807-2816), (2006).
      • , Aspectos actuales y perspectivas de futuro del tratamiento de la artritis reumatoide, Medicine - Programa de Formaci?n M?dica Continuada Acreditado, 10.1016/S0211-3449(06)74450-2, 9, 69, (4436-4442), (2006).
      • , Leflunomide in the treatment of rheumatoid arthritis, Expert Review of Clinical Immunology, 10.1586/1744666X.2.1.17, 2, 1, (17-31), (2014).
      • , Present and future of combination therapy of autoimmune diseases, Future Rheumatology, 10.2217/17460816.1.6.649, 1, 6, (649-655), (2006).
      • , Combination Therapy for Rheumatoid Arthritis in the Era of Biologicals, HSS Journal, 10.1007/s11420-005-0133-z, 2, 1, (30-41), (2006).
      • , Recommandations de la Société française de rhumatologie pour l'utilisation des agents anti-TNFα chez les personnes souffrant de polyarthrite rhumatoïde, Revue du Rhumatisme, 10.1016/j.rhum.2006.04.005, 73, 7, (726-735), (2006).
      • , Biologic Agents in Rheumatology: Safety Considerations, Rheumatic Disease Clinics of North America, 10.1016/S0889-857X(07)70003-0, 32, (3-10), (2006).
      • , Drug Insight: abatacept for the treatment of rheumatoid arthritis, Nature Clinical Practice Rheumatology, 10.1038/ncprheum0345, 2, 12, (654-660), (2006).
      • , The treatment of psoriasis and psoriatic arthritis: An interdisciplinary approach, Journal of the American Academy of Dermatology, 10.1016/j.jaad.2005.10.052, 54, 3, (S85-S91), (2006).
      • , Rheumatoid Arthritis, The Autoimmune Diseases, 10.1016/B978-012595961-2/50035-4, (417-436), (2006).
      • , New Therapeutics in Rheumatoid Arthritis, Rheumatic Disease Clinics of North America, 10.1016/j.rdc.2005.10.004, 32, 1, (57-74), (2006).
      • , Safety and efficacy of etanercept in the elderly, Aging Health, 10.2217/1745509X.2.2.189, 2, 2, (189-197), (2006).
      • , Recommendations of the French Society for Rheumatology. TNFα antagonist therapy in rheumatoid arthritis, Joint Bone Spine, 10.1016/j.jbspin.2006.04.001, 73, 4, (433-441), (2006).
      • , Anakinra in the treatment of rheumatic disease, Expert Review of Clinical Immunology, 10.1586/1744666X.2.3.331, 2, 3, (331-340), (2014).
      • , Is IL-1 a good therapeutic target in the treatment of arthritis?, Best Practice & Research Clinical Rheumatology, 10.1016/j.berh.2006.06.004, 20, 5, (879-896), (2006).
      • , InforMatrix ® : treatment of rheumatoid arthritis using biologicals , Expert Opinion on Pharmacotherapy, 10.1517/14656566.7.13.1769, 7, 13, (1769-1789), (2006).
      • , The Role of IL‐1 and IL‐1Ra in Joint Inflammation and Cartilage Degradation, Interleukins, 10.1016/S0083-6729(06)74016-X, (371-403), (2006).
      • , Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases, Springer Seminars in Immunopathology, 10.1007/s00281-006-0012-9, 27, 4, (391-408), (2006).
      • , Treatment of rheumatoid arthritis, American Journal of Health-System Pharmacy, 10.2146/ajhp050514, 63, 24, (2451-2465), (2006).
      • , Use of biologics in rheumatoid arthritis: Where are we going?, American Journal of Health-System Pharmacy, 10.2146/ajhp060365, 63, 18_Supplement_4, (S19-S41), (2006).
      • , Targeting interleukin‐15 in patients with rheumatoid arthritis: A proof‐of‐concept study, Arthritis & Rheumatism, 52, 9, (2686-2692), (2005).
      • , Infections Associated with Tumor Necrosis Factor‐α Antagonists, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 25, 9, (1181-1192), (2012).
      • , Clinical Pharmacokinetics of Etanercept: A Fully Humanized Soluble Recombinant Tumor Necrosis Factor Receptor Fusion Protein, The Journal of Clinical Pharmacology, 45, 5, (490-497), (2013).
      • , Non‐tumor necrosis factor biological therapies for rheumatoid arthritis, APLAR Journal of Rheumatology, 8, 2, (77-83), (2005).
      • , Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade, The Journal of Experimental Medicine, 10.1084/jem.20050473, 201, 9, (1479-1486), (2005).
      • , Inflammatory arthritis in the era of the biologics, Clinical and Applied Immunology Reviews, 10.1016/j.cair.2004.11.001, 5, 1, (19-44), (2005).
      • , Etanercept: an introduction, Expert Review of Clinical Immunology, 10.1586/1744666X.1.3.313, 1, 3, (313-323), (2014).
      • , Role of innate immunity cytokines in systemic lupus and systemic onset arthritis, International Congress Series, 10.1016/j.ics.2005.08.018, 1285, (50-54), (2005).
      • , Adverse reactions to biologic agents: Focus on autoimmune disease therapies, Journal of Allergy and Clinical Immunology, 10.1016/j.jaci.2005.03.028, 116, 4, (900-905), (2005).
      • , Tratamiento biol?gico de las enfermedades reum?ticas, Medicine - Programa de Formaci?n M?dica Continuada Acreditado, 10.1016/S0211-3449(05)73559-1, 9, 28, (1830-1839), (2005).
      • , Therapies for rheumatoid arthritis: hope springs eternal, Drug Discovery Today, 10.1016/S1359-6446(05)03636-6, 10, 23-24, (1598-1606), (2005).
      • , RheumatologieRheumatology, Der Internist, 10.1007/s00108-005-1444-3, 46, 8, (882-891), (2005).
      • , Design of effective immunotherapy for human autoimmunity, Nature, 10.1038/nature03727, 435, 7042, (612-619), (2005).
      • , Management Issues with Elderly-Onset Rheumatoid Arthritis, Drugs & Aging, 10.2165/00002512-200522100-00002, 22, 10, (809-822), (2005).
      • , Control and Induction of Autoimmunity by Cytokine and Anti-cytokine Treatments, Molecular Autoimmunity, 10.1007/0-387-24534-0_23, (329-345), (2005).
      • , Rheumatoid arthritis: non-tumor necrosis factor targets, Current Opinion in Rheumatology, 10.1097/01.bor.0000159927.19891.eb, 17, 3, (242-246), (2005).
      • , Behandeling van reuma met de combinatie van etanercept en anakinra, Medisch-Farmaceutische Mededelingen, 10.1007/BF03058427, 42, 7, (196-196), (2004).
      • , ?Biologics? bei der rheumatoiden ArthritisCost effectiveness of biologics in the treatment of rheumatoid arthritis, Der Internist, 10.1007/s00108-004-1297-1, 45, 12, (1402-1406), (2004).
      • , Biothérapies émergentes dans la polyarthrite rhumatoïde, Revue du Rhumatisme, 10.1016/j.rhum.2004.07.012, 71, 10-11, (848-853), (2004).
      • , Gene therapy for autoimmune diseases: quo vadis?, Nature Reviews Immunology, 10.1038/nri1459, 4, 10, (800-811), (2004).
      • , Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis, Expert Opinion on Biological Therapy, 10.1517/14712598.4.8.1333, 4, 8, (1333-1344), (2005).
      • , A comparison of cytokine-based approaches to treat autoimmune disorders, Drug Discovery Today: Therapeutic Strategies, 10.1016/j.ddstr.2004.09.010, 1, 3, (275-280), (2004).
      • , Blocking the effect of interleukin-1 and tumor necrosis factor in rheumatoid arthritis is well tolerated and effective, Therapy, 10.2217/14750708.1.2.255, 1, 2, (255-266), (2004).
      • , The trials of anakinra, The Lancet, 10.1016/S0140-6736(04)16999-7, 364, 9437, (827-828), (2004).
      • , Durability and Rapidity of Response to Anakinra in Patients with Rheumatoid Arthritis, Drugs, 10.2165/00003495-200464220-00001, 64, 22, (2493-2501), (2004).
      • , Rheumatoid arthritis: pathogenic mechanisms and therapeutic targets, Drug Discovery Today: Disease Mechanisms, 10.1016/j.ddmec.2004.10.006, 1, 3, (289-295), (2004).
      • , Emerging biological therapies in rheumatoid arthritis, Joint Bone Spine, 10.1016/j.jbspin.2004.07.008, 71, 6, (470-474), (2004).
      • , Tumour necrosis factor α as a therapeutic target for immune-mediated inflammatory diseases, Current Opinion in Biotechnology, 10.1016/j.copbio.2004.09.005, 15, 6, (557-563), (2004).
      • , Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases, Nature Reviews Rheumatology, 10.1038/nrrheum.2017.22, 13, 4, (217-233), (2017)., (2017).
      • , Biologic agents in osteoarthritis: hopes and disappointments, Nature Reviews Rheumatology, 10.1038/nrrheum.2013.44, 9, 7, (400-410), (2013)., (2013).
      • , Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies, Nature Medicine, 10.1038/nm.3897, 21, 7, (730-738), (2015)., (2015).
      • , Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD012591, (2017).
      • , The pathogenesis of rheumatoid arthritis: new insights from old clinical data?, Nature Reviews Rheumatology, 10.1038/nrrheum.2012.23, 8, 4, (235-243), (2012)., (2012).
      • , Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis, Rheumatology, 10.1093/rheumatology/ken491, 48, 4, (440-441), (2009).
      • , Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA), Cochrane Database of Systematic Reviews, 10.1002/14651858.CD012437, (2016).
      • , Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD012183, (2016).
      • , TNF biology, pathogenic mechanisms and emerging therapeutic strategies, Nature Reviews Rheumatology, 10.1038/nrrheum.2015.169, 12, 1, (49-62), (2015)., (2015).
      • , Anakinra for rheumatoid arthritis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005121.pub3, (2009).
      • , The problem of choice: current biologic agents and future prospects in RA, Nature Reviews Rheumatology, 10.1038/nrrheum.2013.8, 9, 3, (154-163), (2013)., (2013).
      • , Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations, Rheumatology, 10.1093/rheumatology/ken190, 47, 7, (1054-1057), (2008).
      • , Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD012657, (2017).
      • , Adverse effects of biologics: a network meta-analysis and Cochrane overview, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008794.pub2, (2011).
      • , Inhibition of Acute Lung Injury by TNFR-Fc through Regulation of an Inflammation-Oxidative Stress Pathway, PLOS ONE, 10.1371/journal.pone.0151672, 11, 3, (e0151672), (2016).
      • , Inflammation meets cancer, with NF-κB as the matchmaker, Nature Immunology, 10.1038/ni.2060, 12, 8, (715-723), (2011)., (2011).
      • , Trojan horses and guided missiles: targeted therapies in the war on arthritis, Nature Reviews Rheumatology, 10.1038/nrrheum.2015.17, 11, 6, (328-337), (2015)., (2015).
      • , Treatment with Biologicals in Rheumatoid Arthritis: An Overview, Rheumatology and Therapy, 10.1007/s40744-017-0073-3, (2017).
      • , Etanercept for the treatment of rheumatoid arthritis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004525.pub2, (2013).
      • , Interleukin-1 Receptor Blockade in Perinatal Brain Injury, Frontiers in Pediatrics, 10.3389/fped.2014.00108, 2, (2014).
      • , Advances in use of immunomodulatory agents—a rheumatology perspective, Nature Reviews Gastroenterology & Hepatology, 10.1038/nrgastro.2015.65, 12, 6, (363-368), (2015)., (2015).
      • , Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis, Rheumatology, 10.1093/rheumatology/key173, (2018).
      • , The current state of the art for biological therapies and new small molecules in inflammatory bowel disease, Mucosal Immunology, 10.1038/s41385-018-0050-3, (2018).
      • , Strategies toward rheumatoid arthritis therapy; the old and the new, Journal of Cellular Physiology, , (2018).